SynthesisFrontiers in immunology2022
Update on Tenosynovial Giant Cell Tumor, an Inflammatory Arthritis With Neoplastic Features.
Synthesis in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 36 citations in OpenAlex.
- Expert Perspectives on TGCT and the Outcomes of the Phase 3 MANEUVER Study of Pimicotinib Presented at ASCO and ESMO 2025: A Podcast Discussion.Advances in therapy · 2026Article
- A Case Report of Endoscopic Anterior Resection Combined with Intraoperative Computed Tomographic Navigation for Tenosynovial Giant Cell Tumor of the Upper Cervical Spine.Spine surgery and related research · 2026Article
- Pexidartinib: Current advances in the symptomatic treatment of tenosynovial giant cell tumors.Cancer metastasis reviews · 2026Review
- Two rare intra-articsular knee disorders with overlapping symptoms: separate case reports of tenosynovial giant cell tumour and lipoma arborescens and literature review.BMC musculoskeletal disorders · 2026Review
- Tenosynovial Giant Cell Tumor (TGCT) in the Hip Joint With anCase reports in orthopedics · 2026Article
- Uncommon Localization of Tenosynovial Giant Cell Tumor in the Coracoclavicular Ligament: Diagnostic Challenges.The American journal of case reports · 2025Article
- Tenosynovial giant cell tumor and its differential diagnosis in children.Pediatric radiology · 2025Review
- Case Report: Pigmented Villonodular Synovitis in a Patient With Sjögren's Syndrome.International journal of rheumatic diseases · 2025Article
- IFNγ production during cell interactions distinguishes localized from diffuse pigmented villonodular synovitis and rheumatoid arthritis.Arthritis research & therapy · 2025Article
- Tenosynovial Giant Cell Tumor Involving Quadriceps Muscle - A Case Report of Two Cases.Journal of orthopaedic case reports · 2025Article
- Tenosynovial giant cell tumours of the foot and ankle: a retrospective single centre experience with surgical treatment of 34 cases.BMC cancer · 2025Article
- Mechanistic Study of CD90-Positive Synovial Fibroblasts in the Invasion and Recurrence of Pigmented Villonodular Synovitis.Journal of inflammation research · 2025Article
- Case Report: Giant cell lesions in the Maxillofacial region: diagnostic points and treatment strategies.Frontiers in oncology · 2025Article
- Article
- Invasion Patterns and Long-Term Clinical Outcomes of Diffuse Tenosynovial Giant Cell Tumor of the Ankle Joint.Cureus · 2024Article
- Diffuse-Type Tenosynovial Giant Cell Tumor: What Are the Important Findings on the Initial and Follow-Up MRI?Cancers · 2024Review
- Real-world drug utilization and treatment patterns in patients with tenosynovial giant cell tumors in the USA.Future oncology (London, England) · 2024Observational
- Identification of potential diagnostic biomarkers for tenosynovial giant cell tumour by integrating microarray and single-cell RNA sequencing data.Journal of orthopaedic surgery and research · 2023Article
- Diagnostic Superiority of Dual-Time Point [Diagnostics (Basel, Switzerland) · 2023Article
- Synoviocytes from pigmented villonodular synovitis are less sensitive to cadmium-induced cell death than synoviocytes from rheumatoid arthritis.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is a chronic inflammatory disease that leads to joint destruction and bone erosion. Even if many treatments were developed with success in the last decades, some patients fail to respond, and disease chronicity is still a burden. Mechanisms involved in such resistance may include molecular changes in stromal cells. Other explanations can come from observations of tenosynovial giant cell tumor (TGCT), first considered as an inflammatory arthritis, but with unusual neoplastic features. TGCT leads to synovium hypertrophy and hyperplasia with hemosiderin deposition. It affects young adults, resulting in secondary osteoarthritis and increased morbidity. TGCT shows clinical, histological and genetic similarities with RA but affecting a single joint. However, the monoclonality of some synoviocytes, the presence of translocations and rare metastases also suggest a neoplastic disease, with some features common with sarcoma. TGCT is more probably in an intermediate situation between an inflammatory and a neoplastic process, with a main involvement of the proinflammatory cytokine CSF-1/CSF1R signaling axis. The key treatment option is surgery. New treatments, derived from the RA and sarcoma fields, are emerging. The tyrosine kinase inhibitor pexidartinib was recently FDA-approved as the first drug for severe TGCT where surgery is not an option. Options directly targeting the excessive proliferation of synoviocytes are at a preclinical stage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.